Introduction
Several bacterial toxins (for example, those produced by Bacillus anthracis and by Bordetella pertussis) and plant toxins (such as ricin) must enter the target cell in order to exert their effects, and the high cytotoxicity of these molecules, in tissue culture and in vivo, provides ample evidence of their efficient translocation across the host cell plasma membrane. The majority of these bacterial and plant toxins bind to specific cell-surface proteins, and enter the cells by endocytosis. However, it has been suggested that some proteins can enter cells in a receptorindependent (and, perhaps, temperature-independent) manner, by penetrating and navigating the cell membrane, thereby gaining access to the cytosol. A number of proteins are thought to be capable of this unexpected maneuver (reviewed in Ref. 1) , but three proteins in particular have been studied: two from viruses (the human immunodeficiency virus type 1 (HIV-1) tat protein 2 and the herpes simplex virus VP22 protein 3 ) and one from drosophila (the antennapedia gene product 4 ). All three proteins bind to nucleic acids, and contain strong nuclear localization signals. 1 Furthermore, in vitro analyses of these proteins have mapped the apparent translocatory functions to short (~11-34 amino acid) regions which have been termed protein transduction domains (PTDs). These PTDs are composed of basic amino acids which in fact, are the residues which bind to DNA or RNA when the native proteins exert their regulatory activity.
The capacity of a very short sequence motif to transport an attached protein into the cytosol would have many possible applications, not least in immunology and vaccine development. For example, many antiviral vaccines rely on the induction of CD8 + T cell responses, but this usually requires that the protein be synthesized within the cytosol of antigen presenting cells (APCs). However, it has been shown that foreign protein introduced directly into the cytosol of an APC can induce CD8 + T cell responses, 5 and this presents an obvious opportunity by which to exploit the apparent activity of PTDs. We hypothesized that the inclusion of the HIV tat PTD in a DNA vaccine might allow the PTD-antigen fusion product to exit the transfected cell in which it was synthesized, and enter the cytosol of neighboring cells, thereby increasing the number of host cells on which the plasmid-encoded antigen was presented to the host immune system. Using an epitope encoded as an isolated 'minigene', we have shown that the addition of a PTD markedly enhances antigen presentation by transfected cells. However, contrary to expectations, this enhancement did not appear to be mediated by intercellular transfer of the PTD-linked epitope. 6 To further investigate the potential of PTDs in vaccine formulation, we have fused an open reading frame encoding the HIV tat PTD to minigene epitopes, full-length antigenic proteins, and marker proteins, and have evaluated the effects in tissue culture and in vivo. + T cells, and the addition of the HIV PTD substantially increased this number to~13%. The enhancing effect of the PTD on the minigene epitope required that the PTD be fused to the epitope, because co-transfection of the standard minigene plasmid, together with the plasmid encoding the PTD alone, had no enhancing effect (Figure 1b) . These results are consistent with our previously published data, in which we showed a beneficial effect of PTD attachment to a different minigene epitope, and in which we demonstrated that the enhancing effect was unlikely to be mediated by intercellular transfer. 6 We have used a highaffinity T cell receptor to directly detect epitope/MHC complexes on the surface of transfected cells, and have found that the addition of the HIV PTD to a minigene epitope markedly increases epitope presentation by MHC class I molecules (Leifert et al, unpublished data) . However, in marked contrast to the enhancing effect on short epitopes, the addition of the PTD to a plasmid encoding a full-length viral protein had no such effect. The stimulatory capacities of cells transfected with the standard plasmid (pCMV-NP) and the plasmid encoding PTD (pCMV-PTD-NP) were indistinguishable ( Figure 1a ).
Results

Addition
The HIV tat PTD fails to enhance the immunogenicity of a full-length protein encoded by a DNA vaccine
Next, we evaluated the effects of the HIV tat PTD in vivo. Mice were immunized with plasmid DNA vaccines encoding the minigene or the full-length protein, without or with the PTD. Eight and 14 days later, blood was drawn, and peripheral blood mononuclear cells (PBMC) were isolated. The PBMC were incubated with the NP 396 peptide, to stimulate IFN␥ production by epitope-specific CD8 + T cells induced by the DNA vaccine, and the percentage of CD8 + T cells which responded to stimulation, was determined by intracellular cytokine staining (ICCS). The following day (day 15), the mice received a booster dose of the DNA vaccine, and 8 days thereafter (day 23), their antigen-specific CD8 + T cell responses were once again determined by ICCS analysis of PBMC. Representative data for the minigene-immunized mice are shown in Figure 2 . Eight days after a single DNA injection, CD8 + T cell responses in mice immunized with the negative control plasmid, and in mice immunized with the standard minigene plasmid (pCMV-NP 396 ) are indistinguishable, while the response induced by the PTD-epitope plasmid, although low, shows a clear 'cloud' of responding cells. By 2 weeks after immunization, the latter response is clearly superior, confirming our previous findings 6 (using different epitopes, and a different mouse strain) that the attachment of a PTD can improve the immunogenicity of a minigene-based DNA vaccine. However, the PTD had no effect on the immunogenicity of plasmid encoding the full-length protein. As shown in Figure 3 , the responses induced 14 days after a single inoculation of plasmid DNA were not significantly different, regardless of the presence or absence of the PTD, and 8 days after a booster injection, both responses had increased to a similar extent.
Studies in live cells show that the HIV tat PTD fails to direct intercellular transfer of an eGFP fusion product
Our failure to detect substantial intercellular transfer of a PTD-linked minigene epitope, 6 and our demonstration that a PTD does not increase the immunogenicity of a full-length protein (Figures 1 and 3 ) led us to ask whether these sequences were indeed capable of the intercellular transfer for which they are renowned. To this end, we attached the HIV tat PTD to enhanced green fluorescent protein (eGFP), and transfected various tissue culture cells with this plasmid, or with a plasmid encoding eGFP alone. Transfection experiments have been carried out by others but, in most of those experiments, the distribution of marker protein was determined in fixed cells. We considered it better to evaluate eGFP expression in living cells and we have done so not only by fluorescence microscopy, but also by flow cytometry, which permits an objective and accurate quantitation of the numbers of cells expressing eGFP, and the level of eGFP expression in each cell. As shown in Figure 4a (left panel), the percentages of cells containing eGFP were very similar at all time-points following transfection, suggesting that the PTD does not lead to transfer of the marker protein into non-transfected living cells. Others have reported that, following expression of a GFP marker protein fused to the HSV VP22 translocation protein, an intensity gradient of GFP fluorescence is present in the fixed tissue culture cells, with individual brighter cells being surrounded by cells showing less intense signal. 3, [7] [8] [9] This appearance has been interpreted as showing VP22-eGFP transfer from cells expressing the protein (the brighter cells), into nonexpressing cells (the less bright). Therefore, we examined both of our live cell populations for such fluorescence gradients, but were unable to detect them by fluorescence microscopy. Representative photomicrographs are shown in the right panel of Figure 4a . In both populations, there was a range of fluorescence intensities, but both the frequency and the distribution of low-intensity cells appeared similar. To further investigate the relative frequencies of low-intensity cells in the two populations, we quantitated eGFP expression levels in all transfected cells in both populations; the resulting dot plots are shown (Figure 4b, left panel) . The range of fluorescence intensity, from low-expressing to high-expressing cells, was approximately 1000-fold (from~10 to 10 4 ), and there was no obvious difference in the distribution of intensities between the two transfected populations. To quantitate these distributions, we divided the populations of GFPpositive cells into nine intensity strata, as indicated on the dot plots, then we calculated the proportion of GFPpositive cells in each stratum, as a percentage of total GFP-positive cells in the population. Figure 4b 
The HIV PTD appears to adhere to methanol-fixed cells
In the above studies, we can detect no intercellular transfer of the PTD-NP or PTD-eGFP fusion proteins. Does the addition of the HIV PTD have any effect whatsoever on the behavior of an attached full-length protein? A recent paper strongly suggested that the apparent translocatory effect of VP22 may be an artifact of fixation, which disrupts the membrane of transfected cells, and releases the protein which can then bind, through its strong nuclear localization signal, to the newly exposed structures in adjacent cells. 10 We attempted to duplicate these findings, to test our hypothesis that the PTD -rather than permitting translocation between living cells -instead is 'sticky' and, along with its fusion partner, will bind to neighboring structures if it is released from a transfected cell. Therefore, we followed the procedure of methanol fixation, described in the original paper showing VP22 translocation. 3 Tissue culture cells were transfected with p-eGFP, or with p-PTD-eGFP, and 48 h later were analyzed by fluorescence microscopy. To allow a precise evaluation of the effects, we chose to take photomicrographs of identical fields before and after methanol fixation. As shown in Figure 5 (left panels), eGFP fluorescence is readily detectable in some cells in both transfected populations, but many non-fluorescing cells can also be seen. However, after methanol fixation ( Figure 5 , right panels), a dramatic change occurs in the population of cells which had been transfected with p-PTD-eGFP; fluorescence is detectable in almost all of the cells. This phenomenon is dependent on the HIV PTD, because no such effect occurs after methanol fixation of the population which had been transfected with p-eGFP. If one ignores the live cells, and compares only the two methanol-fixed populations, it is easy to see how one
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Figure 5 PTD-dependent eGFP fluorescence occurs in methanol-fixed cells. HeLa cells were transfected with either p-eGFP or p-PTD-eGFP, and 48 h later the live cells were photographed under fluorescence microscopy (left panels). The cells were then fixed in methanol, and the same fields were photographed (right panels).
might conclude that the addition of the HIV PTD had led to intercellular transfer of the eGFP.
Discussion
The capacity of an extracellular protein, or other moiety, to gain entry to the cell cytosol is not unusual. Many proteins (for example, growth factors and bacterial toxins) and other ligands, such as viruses, bind to specific receptors on the cytoplasmic membrane, and thereafter enter the cell, either via endocytosis, or (in the case of some enveloped viruses) by fusion of the adjacent lipid bilayers. These processes are dependent on specific cell-surface receptors, and do not occur at 4°C (a temperature at which endocytosis is inhibited). The discovery of proteins which apparently could translocate across cell membranes in the absence of specific receptors brought with it the possibility of their being used to enhance the delivery of attached proteins into cells. Subsequent molecular analyses of these translocatory proteins identified short, highly basic sequences which permitted attached proteins to enter cells in the absence of a specific receptor, and at low temperature, excluding standard endocytosis as the entry mechanism. The potential utility of PTDs was clearly demonstrated when the HIV tat PTD was attached to the bacterial enzyme ␤-galactosidase, and injection of the fusion product into mice resulted in the expression of enzyme activity in many tissues, including the brain.
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Widespread ␤-galactosidase expression was dependent upon attachment of the PTD sequence, indicating that the PTD was required for membrane translocation, and could even take the large (~120 kDa) fusion protein across the usually impervious blood-brain barrier.
Observations such as these have led several groups to evaluate the biotechnological potential of PTDs, and of the proteins in which they were originally identified, and several papers have described the apparent intercellular transfer of full-length proteins attached to the HSV VP22 protein, and to the HIV tat PTD. It is not easy to understand how a highly structured native protein could pass through a lipid bilayer in a temperature-independent manner, and on first principles such translocation should be more efficient if the PTD-linked protein is in a highenergy (denatured) state. Consistent with this, the dramatic in vivo demonstrations of PTD function were achieved using PTD fusion products that had been denatured using chaotropic agents before their in vivo inoculation. [11] [12] [13] [14] The PTD fusion product regains biological activity after entering cells, 15 indicating that native protein is present after the translocation is complete. However, if denaturation is required for efficient translocation, this is very difficult to reconcile with the idea that proteins such as HIV tat and VP22 can pass freely across cell membranes under normal circumstances. One would predict that PTD-containing proteins synthesized in vivo (for example, following a virus infection, or after transfection of plasmid DNA encoding a PTD fusion protein) would be in native conformation, and thus would not be efficiently transferred from one cell to another. In this study, we have generated a PTD fusion construct between the HIV tat PTD, and the full-length nucleoprotein (NP) from lymphocytic choriomeningitis virus (LCMV). The immune responses induced by LCMV NP are extremely well characterized, allowing us to determine whether or not the addition of a PTD enhances immunogenicity, and our data indicate that the addition of the HIV tat PTD had no beneficial effect in vivo ( Figure  3) . In contrast to the lack of effect on a full-length protein, addition of the tat PTD to a minigene-encoded epitope increased antigen presentation in tissue culture ( Figure  1 ), as well as the immune response induced in vivo (Figure 2 ). This enhancing effect does not appear to be mediated by intercellular transfer of the PTD-epitope, 6 and may instead result from increased antigen density on the surface of transfected cells (Leifert et al, unpublished data) . To directly evaluate tat PTD-mediated intercellular protein transfer in real time, in living cells, we generated an HIV tat PTD fusion with the indicator protein, eGFP. Careful quantitation of cells transfected with plasmids encoding eGFP with and without an attached PTD, showed no significant difference in the percentages of cells expressing the marker protein, suggesting that extensive intercellular transfer of PTD-eGFP was not taking place (Figure 4a ). Taken together, our data from Figure 1 to 4a inclusive, argue that the HIV tat PTD sequence has no detectable translocatory activity when attached to a full-length protein synthesized de novo.
Many studies purporting to show intercellular transfer of the HSV VP22 protein, or of fusion products thereof, have shown clearly visible 'gradients' of protein, in which a cell containing abundant protein is surrounded by cells containing lower amounts, consistent with transfer of the fusion protein from one cell, into neighboring cells. 3, 9, 16 From these observations, it was inferred that the brighter cells were those which expressed the fusion protein, some of which escaped from these cells, to be taken up by neighboring cells, resulting in the lower-intensity fluorescence. Therefore, we very carefully scrutinized our PTD-eGFP transfected cells for any evidence of a fluorescence gradient, which might have been indicative of intercellular transfer, but we saw no foci of bright cells with paler satellites (Figure 4a, right panel) . Furthermore, careful quantitative analyses of the intensities of all GFPpositive cells in each population showed very clearly that the distributions of fluorescence intensity were almost identical (Figure 4b) . Thus, the data in this paper and in our previous publication, 6 cast serious doubt on the translocatory activity of the HIV tat PTD, when expressed de novo. Furthermore, several groups have begun to question the apparent translocatory activity of HSV VP22. Many of the reports upon which this phenomenon relies were based on microscopic analyses of methanol-fixed cells, and it has proven difficult to duplicate these observations in live cells. 16, 17 A recent paper strongly suggested that the apparent translocatory effect of VP22 may be an artifact of fixation, whereby the fixative strips away the cell membrane, releasing the VP22 from transfected cells, and thus liberated, the protein binds, through its strong nuclear localization signal, to the exposed nuclei of adjacent cells. 10 We show here ( Figure 5 ) that a similar effect can be seen following methanol fixation of cells transfected with p-PTD-eGFP, and that the resulting ubiquitous fluorescence is dependent on the presence of the PTD. This seemingly indiscriminate binding is consistent with recent demonstrations that the HIV tat PTD can bind to heparin 18 (a negatively charged polysaccharide which is expressed on many cell types), and to uncharacterized components of the extracellular tissue matrix. 19 Thus, we propose that, contrary to current dogma, there is no intrinsic 'unconventional translocatory activity' in the native proteins in which PTD sequences were first identified. Consistent with this, an early, and often overlooked, study of the native HIV tat protein showed that its 'translocation' was temperature-dependent, and most probably occurred by standard absorptive endocytosis. 20 Thus, the mechanism of translocation of native HIV tat differs from that proposed for the HIV tat PTD, indicating that the functions attributed to the PTD may not reflect real biological activity. Nevertheless, the evidence that short basic regions, such as the tat PTD, can effectively enhance the biodistribution of attached marker proteins is strong. 21 How can this apparent paradox be resolved? The lack of receptor specificity, together with the effectiveness of highly basic oligopeptides, suggests that PTD may exert their effects by mediating nonspecific binding to the cell membrane. This hypothesis is supported by the observations that the residues constituting a PTD can be re-arranged without loss of PTD activity, 22 and that a PTD can be replaced by a simple run of arginine residues. 23, 24 We suggest that the highly basic nature of PTD motifs explains the misleading fixation artifact, and also allows binding to the cell surface, after which the bound proteins may be internalized, perhaps by a pathway which favors arginine-rich products. 25 Enhanced cell surface binding, without internalization, has been demonstrated for non-denatured bacterial toxins fused to either the HIV tat PTD, or to the VP22 protein. 26 Thus, addition of a PTD would enhance neither release from, nor entry into, cells. Instead, a PTD would enhance binding of free protein to the cell membrane and, especially if the PTD fusion product had been previously denatured, subsequent entry into the cell would be facilitated. We feel that this hypothesis is consistent with the published data and, if correct, indicates that the term 'protein transduction domain' is an inaccurate representation of the mode of action. Therefore, the term, and its acronym, should be revised. More importantly, this view of 'PTDs', which suggests that they are unlikely to be of great value when the fusion proteins are synthe-sized in vivo, has obvious implications for gene therapy and for vaccine design.
